These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 1376431)

  • 41. Prevention of colon cancer and modulation of aberrant crypt foci, cell proliferation, and apoptosis by retinoids and NSAIDs.
    Pereira MA
    Adv Exp Med Biol; 1999; 470():55-63. PubMed ID: 10709674
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The clinical evaluation of cancer chemoprevention agents: defining and contrasting phase I, II, and III objectives.
    Goodman GE
    Cancer Res; 1992 May; 52(9 Suppl):2752s-2757s. PubMed ID: 1563007
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cancer chemoprevention: progress and promise.
    Kelloff GJ; Sigman CC; Greenwald P
    Eur J Cancer; 1999 Dec; 35(13):1755-62. PubMed ID: 10673988
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The next phase of chemoprevention research.
    Cohen EE; Schilsky RL
    Cancer Prev Res (Phila); 2011 Mar; 4(3):293-5. PubMed ID: 21372026
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Chemoprevention of cancer. Prevention of cancer in groups with increased risk].
    Sanner T; Dybing E
    Tidsskr Nor Laegeforen; 1996 Aug; 116(19):2329-33. PubMed ID: 8804210
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intermediate biomarkers of precancer and their application in chemoprevention.
    Kelloff GJ; Malone WF; Boone CW; Steele VE; Doody LA
    J Cell Biochem Suppl; 1992; 16G():15-21. PubMed ID: 1469895
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chemoprevention of nonmelanoma skin cancer.
    Wright TI; Spencer JM; Flowers FP
    J Am Acad Dermatol; 2006 Jun; 54(6):933-46; quiz 947-50. PubMed ID: 16713450
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chemoprevention of lung cancer.
    Hong WK
    Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):135-41. PubMed ID: 10550838
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemoprevention.
    Greenwald P; Kelloff G; Burch-Whitman C; Kramer BS
    CA Cancer J Clin; 1995; 45(1):31-49. PubMed ID: 7804897
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Progress in cancer chemoprevention.
    Kelloff GJ; Crowell JA; Steele VE; Lubet RA; Boone CW; Malone WA; Hawk ET; Lieberman R; Lawrence JA; Kopelovich L; Ali I; Viner JL; Sigman CC
    Ann N Y Acad Sci; 1999; 889():1-13. PubMed ID: 10668477
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Colon cancer overview.
    Greenwald P
    Cancer; 1992 Sep; 70(5 Suppl):1206-15. PubMed ID: 1511368
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemoprevention of cancer: review of the literature.
    Swan DK; Ford B
    Oncol Nurs Forum; 1997 May; 24(4):719-27. PubMed ID: 9159786
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
    Meyskens FL; Gerner EW
    Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Criteria of evidence to move potential chemopreventive agents into late phase clinical trials.
    Kelly RJ; Lopez-Chavez A; Szabo E
    Curr Drug Targets; 2011 Dec; 12(13):1983-8. PubMed ID: 21158704
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Breast cancer chemoprevention: clinical trials and research.
    Noguchi M; Rose DP; Miyazaki I
    Oncology; 1996; 53(3):175-81. PubMed ID: 8643218
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current status of chemoprevention trials at the National Cancer Institute.
    Nixon DW
    Cancer Invest; 1990; 8(6):625-7. PubMed ID: 2292055
    [No Abstract]   [Full Text] [Related]  

  • 57. Cancer chemoprevention: progress and promise.
    Kelloff GJ; Sigman CC; Greenwald P
    Eur J Cancer; 1999 Dec; 35(14):2031-8. PubMed ID: 10711244
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chemoprevention clinical trials: it is time to turn success into progress.
    Brown PH
    Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1531-2. PubMed ID: 17684123
    [No Abstract]   [Full Text] [Related]  

  • 59. How should we move the field of chemopreventive agent development forward in a productive manner?
    Meyskens FL; Szabo E
    Recent Results Cancer Res; 2005; 166():113-24. PubMed ID: 15648187
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Smokers and urinary genotoxins: implications for selection of cohorts and modulation of endpoints in chemoprevention trials.
    De Flora S; Camoirano A; Bagnasco M; Bennicelli C; van Zandwijk N; Wigbout G; Qian GS; Zhu YR; Kensler TW
    J Cell Biochem Suppl; 1996; 25():92-8. PubMed ID: 9027604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.